Hospital
Hoke Healthcare LLC
Hoke Healthcare LLC was paid $24.80M by Medicaid between Jan 2018 and Dec 2024, across 116 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoHOKE HEALTHCARE LLC
RAEFORD, NC 28376
RAEFORD, NC 28376
33aNPI1750788238assigned 11/26/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$24.80M
24GClaims569,843
24DCodes billed116
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#21 of 92
Median peer was paid$11.47M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FISER, JOSEPH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,605 | $1.95M | |
| 2019 | 70,685 | $2.27M | |
| 2020 | 62,391 | $1.42M | |
| 2021 | 84,015 | $3.33M | |
| 2022 | 96,599 | $5.28M | |
| 2023 | 100,528 | $4.97M | |
| 2024incomplete | 109,020 | $5.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 46,746 | 41,379 | $7.48M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 16% | 46,528 | 41,857 | $3.94M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 14,205 | 12,278 | $3.13M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 10% | 16,683 | 14,856 | $2.52M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 1,472 | 1,228 | $1.09M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 17,594 | 14,932 | $1.04M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.2% | 850 | 719 | $541K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 11,498 | 9,514 | $415K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 15,619 | 10,842 | $381K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 8,583 | 7,438 | $346K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 4,154 | 3,479 | $332K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 13,596 | 11,526 | $322K |
104 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 5,220 | $275K |
| 80053 | Comprehensive metabolic panel | 1.1% | 32,858 | $274K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 1,252 | $267K |
| 85027 | <1% | 30,768 | $186K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,918 | $173K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,308 | $161K |
| 81025 | <1% | 19,250 | $145K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,305 | $144K |
| J3490 | Unclassified drugs | <1% | 43,109 | $135K |
| 87400 | <1% | 8,076 | $111K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,248 | $97K |
| 99285 | Emergency room visit (most serious) | <1% | 377 | $93K |
| 36415 | Collection of venous blood by venipuncture | <1% | 43,696 | $92K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,834 | $88K |
| 84484 | <1% | 11,048 | $87K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,232 | $74K |
| 81001 | <1% | 22,508 | $73K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,567 | $67K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,566 | $67K |
| 83690 | <1% | 9,866 | $66K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,361 | $66K |
| G0378 | Hospital observation service, per hour | <1% | 283 | $64K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,422 | $53K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 593 | $46K |
| 76801 | <1% | 169 | $29K | |
| A9270 | Non-covered item or service | <1% | 24,119 | $24K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,545 | $21K |
| 81003 | <1% | 8,218 | $18K | |
| 84702 | <1% | 1,610 | $17K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,671 | $17K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,243 | $16K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 330 | $16K |
| 87070 | <1% | 1,364 | $14K | |
| 96376 | <1% | 204 | $12K | |
| 85730 | <1% | 2,534 | $12K | |
| 87420 | <1% | 858 | $12K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,748 | $11K |
| 87088 | <1% | 1,389 | $11K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 367 | $9K |
| 83735 | <1% | 1,411 | $8K | |
| 87210 | <1% | 2,070 | $8K | |
| 85610 | <1% | 2,652 | $8K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,269 | $8K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 55 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,109 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 550 | $6K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 192 | $5K |
| 82553 | <1% | 702 | $5K | |
| 82550 | <1% | 1,149 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 236 | $5K |
| 73562 | <1% | 39 | $4K | |
| 83605 | <1% | 365 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 111 | $3K |
| 0012A | <1% | 58 | $3K | |
| 87040 | <1% | 329 | $3K | |
| 80061 | Lipid panel | <1% | 196 | $3K |
| 0353U | <1% | 223 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 303 | $3K |
| 0001A | <1% | 35 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 13 | $2K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 153 | $2K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 96 | $2K |
| 82947 | <1% | 679 | $2K | |
| 0011A | <1% | 43 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 30 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 107 | $2K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 358 | $1K |
| 73630 | <1% | 13 | $1K | |
| 73610 | <1% | 14 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 162 | $918.60 |
| 82652 | <1% | 25 | $871.89 | |
| 86592 | <1% | 194 | $842.92 | |
| 87077 | <1% | 145 | $835.93 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 19 | $723.12 |
| 83880 | <1% | 15 | $486.59 | |
| 83021 | <1% | 25 | $483.80 | |
| 82077 | <1% | 311 | $459.15 | |
| 87340 | <1% | 42 | $446.80 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 80 | $419.39 |
| 86900 | <1% | 112 | $415.55 | |
| 86901 | <1% | 112 | $415.55 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $387.30 |
| 86140 | <1% | 90 | $384.00 | |
| 82150 | <1% | 55 | $383.60 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 28 | $363.62 |
| 81002 | <1% | 45 | $295.99 | |
| 94760 | <1% | 19 | $293.34 | |
| 85379 | <1% | 57 | $286.78 | |
| 80143 | <1% | 120 | $236.51 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 50 | $182.28 |
| 86787 | <1% | 12 | $176.55 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 74 | $176.50 |
| 82248 | <1% | 30 | $143.75 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $123.06 |
| 86850 | <1% | 12 | $110.00 | |
| 80179 | <1% | 118 | $104.39 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 27 | $96.81 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 30 | $88.73 |
| 87186 | <1% | 14 | $86.16 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 17 | $78.69 |
| J2704 | Injection, propofol, 10 mg | <1% | 16 | $64.90 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 76 | $45.63 |
| 81005 | <1% | 16 | $27.75 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 546 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFISER, JOSEPH (VP CORP REVENUE CYCLE/MANAGED CARE)
Parent organizationCUMBERLAND COUNTY HOSPITAL SYSTEM INC
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.